These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981 [TBL] [Abstract][Full Text] [Related]
29. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I; Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525 [TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966 [TBL] [Abstract][Full Text] [Related]
31. Immediate placebo effect in Parkinson's disease--is the subjective relief accompanied by objective improvement? Fregni F; Boggio PS; Bermpohl F; Maia F; Rigonatti SP; Barbosa ER; Pascual-Leone A Eur Neurol; 2006; 56(4):222-9. PubMed ID: 17057382 [TBL] [Abstract][Full Text] [Related]
32. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge. Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692 [TBL] [Abstract][Full Text] [Related]
34. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606 [TBL] [Abstract][Full Text] [Related]
35. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709 [TBL] [Abstract][Full Text] [Related]
36. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Marras C; Lang A; Krahn M; Tomlinson G; Naglie G; Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356 [TBL] [Abstract][Full Text] [Related]
37. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
38. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM; Delville Y; Schallert T Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106 [TBL] [Abstract][Full Text] [Related]
39. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
40. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Metman LV; Sethy VH; Roberts JR; Bravi D; Hoff JI; Mouradian MM; Chase TN Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]